The announcements include:

• Anthem Blue Cross and Blue Shield eligible members will be the first commercially insured patients in the United States to benefit from medical policy coverage supporting blood-based biomarker testing for Alzheimer’s disease.
• Publication of new peer-reviewed study comparing LucentAD® Complete against an immunoprecipitation mass spectrometry (IP-MS) method on a shared patient cohort, demonstrating strong diagnostic parity while combining five biomarkers across amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.
  • New clinical data presented at the Alzheimer’s Association International Conference (AAIC) 2026 highlighting the role of multi-biomarker testing in supporting patient triage and supporting earlier clinical decision making.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.